About: From COVID-19 research to vaccine application: why might it take 17 months not 17 years and what are the wider lessons?

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: From COVID-19 research to vaccine application: why might it take 17 months not 17 years and what are the wider lessons? Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	From COVID-19 research to vaccine application: why might it take 17 months not 17 years and what are the wider lessons?
Creator	Grant, Jonathan Hanney, Stephen Sussex, Jon Wooding, Steven
source	Medline; PMC
abstract	It is often said that it takes 17 years to move medical research from bench to bedside. In a coronavirus disease (COVID-19) world, such time-lags feel intolerable. In these extraordinary circumstances could years be made into months? If so, could those lessons be used to accelerate medical research when the crisis eases? To measure time-lags in health and biomedical research as well as to identify ways of reducing them, we developed and published (in 2015) a matrix consisting of overlapping tracks (or stages/phases) in the translation from discovery research to developed products, policies and practice. The matrix aids analysis by highlighting the time and actions required to develop research (and its translation) both (1) along each track and (2) from one track to another, e.g. from the discovery track to the research-in-humans track. We noted four main approaches to reducing time-lags, namely increasing resources, working in parallel, starting or working at risk, and improving processes. Examining these approaches alongside the matrix helps interpret the enormous global effort to develop a vaccine for the 2019 novel coronavirus SARS-CoV-2, the causative agent of COVID-19. Rapid progress in the discovery/basic and human research tracks is being made through a combination of large-scale funding, work being conducted in parallel (between different teams globally and through working in overlapping tracks), working at greater (but proportionate) risk to safety than usual, and adopting various new processes. The overlapping work of some of the teams involves continuing animal research whilst entering vaccine candidates into Phase I trials alongside planning their Phase II trials. The additional funding available helps to reduce some of the usual financial risks in moving so quickly. Going forward through the increasingly large human trials for safety, dosage and efficacy, it will be vital to overlap work in parallel in the often challenging public policy and clinical tracks. Thus, regulatory and reimbursement bodies are beginning and preparing rapid action to pull vaccines proving to be safe and effective through to extraordinarily rapid application to the general population. Monitoring the development of a COVID-19 vaccine using the matrix (modified as necessary) could help identify which of the approaches speeding development and deployment could be usefully applied more widely in the future.
has issue date	2020-06-08(xsd:dateTime)
bibo:doi	10.1186/s12961-020-00571-3
bibo:pmid	32513202
has license	cc-by
sha1sum (hex)	97135b43ae17f4127ca7dc7a4f31c217afa524e4
schema:url	https://doi.org/10.1186/s12961-020-00571-3
resource representing a document's title	From COVID-19 research to vaccine application: why might it take 17 months not 17 years and what are the wider lessons?
has PubMed Central identifier	PMC7276964
has PubMed identifier	32513202
schema:publication	Health Res Policy Syst
resource representing a document's body	covid:97135b43ae17f4127ca7dc7a4f31c217afa524e4#body_text
is schema:about of	named entity 'Monitoring' named entity 'reducing' named entity 'accelerate' named entity 'Phase I trials' named entity 'global' covid:arg/97135b43ae17f4127ca7dc7a4f31c217afa524e4 named entity 'additional' named entity 'medical' named entity 'development' named entity 'vaccines' named entity 'discovery' named entity 'Going' named entity 'medical' named entity 'move' named entity 'proportionate' named entity 'COVID-19' named entity 'public policy' named entity 'causative agent' named entity 'general' named entity 'helps' named entity 'tracks' named entity 'clinical trial' named entity 'cognitive behavioural' named entity 'Jenner Institute' named entity 'epidemic' named entity 'MERS-CoV' named entity 'Phase IV trial' named entity 'vaccine' named entity 'respiratory distress' named entity 'COVID-19' named entity 'intellectual property' named entity 'Commonwealth Scientific and Industrial Research Organisation' named entity 'human trials' named entity 'University of Oxford' named entity 'Medicines for Malaria Venture' named entity 'social distancing' named entity 'Bill & Melinda Gates Foundation' named entity 'Phase I clinical trial' named entity 'decision-makers' named entity 'COVID-19' named entity 'vaccine' named entity 'United Kingdom' named entity 'COVID-19 vaccine' named entity 'NIAID' named entity 'regulatory approval' named entity 'animal testing' named entity 'COVID-19' named entity 'vaccine' named entity 'mass production' named entity 'linear representation' named entity 'mortality rates' named entity 'vaccine' named entity 'public policy' named entity 'Biomedical Advanced Research and Development Authority' named entity 'time lapse' named entity 'cognitive behavioural' named entity 'animal testing' named entity 'regulatory approval' named entity 'animal research' named entity 'Jenner Institute' named entity 'NIAID' named entity 'Buxton' named entity 'public policy' named entity 'Swedish' named entity 'vaccine' named entity 'causative agent' named entity 'preclinical research' named entity 'immune response' named entity 'vaccine against COVID-19' named entity 'WHO' named entity 'corticosteroids' named entity 'United States' named entity 'vaccine' named entity 'Jenner Institute' named entity 'AstraZeneca' named entity 'Jenner Institute' named entity 'HIV/AIDS' named entity 'France'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software